Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NTLA Intellia Therapeutics Inc

未开盘 07-08 16:00:00 EDT

16.84

-0.59

-3.38%

盘后16.84

+0.00-0.03%

19:58 EDT

最高17.09	最低16.35	成交量354.74万
今开16.81	昨收17.43	日振幅4.25%
总市值23.58亿	流通市值22.38亿	总股本1.40亿
成交额5,938万	换手率2.67%	流通股本1.33亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NTLA","market":"US","secType":"STK","nameCN":"Intellia Therapeutics Inc","latestPrice":16.84,"timestamp":1783540800000,"preClose":17.43,"halted":0,"volume":3547409,"hourTrading":{"tag":"盘后","latestPrice":16.835,"preClose":16.84,"latestTime":"19:58 EDT","volume":131502,"amount":2214819.8346,"timestamp":1783555119200,"change":-0.005,"changeRate":-0.000297,"amplitude":0.019002},"delay":0,"changeRate":-0.03384968445209408,"floatShares":132900080,"shares":140000000,"eps":-3.52,"marketStatus":"未开盘","change":-0.59,"latestTime":"07-08 16:00:00 EDT","open":16.81,"high":17.09,"low":16.35,"amount":59382846.23002,"amplitude":0.042456,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.52,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1783584000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1462507200000,"exchange":"NASDAQ","adjPreClose":17.43,"preHourTrading":{"tag":"盘前","latestPrice":16.86,"preClose":17.43,"latestTime":"09:28 EDT","volume":23244,"amount":389292.232056,"timestamp":1783517283038,"change":-0.57,"changeRate":-0.032702,"amplitude":0.045324},"postHourTrading":{"tag":"盘后","latestPrice":16.835,"preClose":16.84,"latestTime":"19:58 EDT","volume":131502,"amount":2214819.8346,"timestamp":1783555119200,"change":-0.005,"changeRate":-0.000297,"amplitude":0.019002},"volumeRatio":0.947728,"impliedVol":0.8576,"impliedVolPercentile":0.2669},"requestUrl":"/m/hq/s/NTLA","defaultTab":"news","newsList":[{"id":"2645819136","title":"基因编辑概念普升 安捷伦科技(A)领涨4.21% 机构指美国FDA相关疗法审评新规利好相关标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2645819136","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645819136?lang=zh_cn&edition=full","pubTime":"2026-06-24 22:21","pubTimestamp":1782310862,"startTime":"0","endTime":"0","summary":"金吾财讯 | 美股基因编辑概念普升，截至发稿，安捷伦科技 (A) 涨 4.21%，Beam Therapeutics (BEAM) 涨 3.55%，Intellia Therapeutics (NTLA) 涨 2.95%，Editas Medicine (EDIT) 涨 2.17%，福泰制药 (VRTX) 涨 1.28%。消息面上，建银国际新近研究认为，美国FDA近期发布了基因编辑疗法审评新规，允许药企在提供充分科学可比性论证的前提下，引用“先验知识”或既往成熟研究数据以加速研发，此举这标志着基因编辑疗法审评思路的重要转变，直接利好拥有相关技术平台的企业。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/NDViNTE0MThlOGIzNGVjYjVmZmFmNTJlOTIxNzAyOTY1ODYyNw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDViNTE0MThlOGIzNGVjYjVmZmFmNTJlOTIxNzAyOTY1ODYyNw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301875","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","LU0417517546.SGD","LU0432979614.USD","BK4533","LU0079474960.USD","LU2236285917.USD","LU2362541273.HKD","NTLA","LU0109394709.USD","IE00BFTCPJ56.SGD","LU0256863811.USD","LU1585245621.USD","LABU","LU2413666699.HKD","LU2041044095.USD","SG9999013999.USD","LU2089279066.USD","BK4611","LU1035775433.USD","A","BK4121","LU0234570918.USD","VRTX","IE00BN0W2W23.USD","IE00BZ9MQY76.HKD","LU0889565916.HKD","BK4139","LU2462157665.USD","IE00BJT1NW94.SGD","LU1674673691.USD","IE00B19Z9Z06.USD","LU2092937221.SGD","IE00B894F039.SGD","LU0058720904.USD","LU2324357040.USD","SGXZ57979304.SGD","LU2229751404.USD","SG9999001176.SGD","IE00BN0W2V16.EUR","IE00BJJMRZ35.SGD","BK4567","LU2362540622.SGD","EDIT","LU0320765992.SGD","LU1861559042.SGD","LU1674673428.USD","IE00B19Z3581.USD","BK4588","BK4505","BEAM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123375802","title":"Intellia Therapeutics旗下Haleo研究达到主要终点，Lonvo-Z组平均月发作次数降低87% (P<0.0001)","url":"https://stock-news.laohu8.com/highlight/detail?id=1123375802","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123375802?lang=zh_cn&edition=full","pubTime":"2026-06-13 19:37","pubTimestamp":1781350635,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics宣布，其Haleo研究成功达到主要终点。数据显示，在Lonvo-Z治疗组中，患者平均每月发作次数实现了高达87%的显著降低，且该结果具有高度统计学意义（P值小于0.0001）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1861559042.SGD","BK4585","LU1861558580.USD","NTLA","BK4556","BK4588","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122255214","title":"Intellia Therapeutics启动Lonvo-Z滚动BLA提交，预计2027年上半年在美国上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1122255214","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122255214?lang=zh_cn&edition=full","pubTime":"2026-06-13 19:33","pubTimestamp":1781350398,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics已正式启动其基因编辑疗法Lonvo-Z向美国食品药品监督管理局（FDA）的滚动生物制品许可申请（BLA）提交程序。这一关键步骤标志着该疗法向商业化迈出了重要一步。公司预计，若后续审查顺利，Lonvo-Z有望于2027年上半年在美国市场正式推出。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4535","NTLA","BK4588","BK4556","BK4585","LU1861558580.USD","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170241565","title":"Intellia Therapeutics公布Lonvoguran Ziclumeran (Lonvo-Z)治疗遗传性血管性水肿的3期试验更多积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1170241565","media":"美股速递","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170241565?lang=zh_cn&edition=full","pubTime":"2026-06-13 19:31","pubTimestamp":1781350278,"startTime":"0","endTime":"0","summary":"生物技术公司Intellia Therapeutics Inc公布了其候选疗法Lonvoguran Ziclumeran（研发代号Lonvo-Z）在治疗遗传性血管性水肿患者中的最新3期临床试验数据，结果显示出持续的积极疗效与安全性。\n此次公布的数据进一步巩固了该疗法在关键后期研究中的表现，为后续的监管申请提供了有力支持。遗传性血管性水肿是一种罕见的遗传性疾病，患者会反复出现皮下或黏膜下组织的严重肿胀，目前仍存在未满足的临床需求。\n公司表示，这些额外的积极结果增强了他们对Lonvo-Z潜力的信心，并计划持续推进相关开发工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4535","BK4556","BK4585","LU1861558580.USD","NTLA","BK4588","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146733927","title":"异动解读｜Intellia Therapeutics盘中上涨8.01%，报13.62美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1146733927","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146733927?lang=zh_cn&edition=full","pubTime":"2026-05-28 03:35","pubTimestamp":1779910518,"startTime":"0","endTime":"0","summary":"5月28日，Intellia Therapeutics盘中上涨8.01%，报13.62美元/股，成交额7197.21万美元。Intellia Therapeutics所在的生物科技行业中，个股中，再生元制药公司跌0.43%，艾伯维公司涨1.12%，安进涨0.47%，福泰制药涨0.71%，吉利德科学涨0.04%。Intellia Therapeutics是一家领先的基因编辑公司，专注于利用CRISPR/Cas9系统生物工具开发潜在治愈性疗法，致力于通过单一疗程永久编辑疾病相关基因，发展新一代治疗产品。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102451903","title":"异动解读 | Intellia Therapeutics盘中大跌8.12%，一季度营收下滑与生物科技板块疲软成主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1102451903","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102451903?lang=zh_cn&edition=full","pubTime":"2026-05-19 00:07","pubTimestamp":1779120469,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics（NTLA）今日盘中股价大幅下挫，跌幅达8.12%，引发了市场关注。消息面上，此次下跌主要受到两方面因素影响。首先，公司此前公布的一季度业绩显示营收承压，一季度营收同比下降约9.6%，这加重了市场对于这家尚未有商业化产品的基因编辑公司其现金消耗速度以及研发管线推进节奏的担忧。其次，生物科技板块今日整体延续弱势，板块情绪疲软进一步放大了个股的跌幅。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190806195","title":"异动解读 | Intellia Therapeutics盘中大跌8.33%，一季度营收下滑及板块情绪疲软拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1190806195","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190806195?lang=zh_cn&edition=full","pubTime":"2026-05-15 03:37","pubTimestamp":1778787472,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics（股票代码：NTLA）今日盘中股价大跌8.33%，引起了市场的广泛关注。消息面上，公司近日公布的第一季度业绩报告显示，其营收表现承压。尽管每股净亏损优于市场预期且同比收窄，但一季度营收为1504.8万美元，较去年同期下降约9.6%。对于尚未有商业化产品的生物科技公司而言，营收下滑的信号加重了市场对其现金消耗及研发管线推进节奏的担忧。此外，同日内生物科技板块整体情绪偏弱，同行业公司股价亦出现显著下跌，进一步放大了Intellia Therapeutics的个股跌幅。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161536536","title":"异动解读 | Intellia Therapeutics因1.8亿美元股票出售盘前大跌9.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=1161536536","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161536536?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:54","pubTimestamp":1777463676,"startTime":"0","endTime":"0","summary":"基因编辑公司Intellia Therapeutics Inc今日盘前股价大跌9.25%，引发了市场关注。消息面上，此次股价下跌主要与公司宣布的一项融资活动有关。Intellia Therapeutics公布了1.8亿美元的后续发行定价，计划发行约1,670万股，发行价为每股10.75美元，这一价格较其前一交易日的收盘价有显著折让，幅度达到18.6%。此类股权融资通常会增加市场流通股数量，并对现有股价产生稀释压力，从而导致股价在短期内承压下跌。高盛、花旗集团和杰富瑞担任此次发行的联合簿记管理人。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170978288","title":"异动解读 | 券商上调目标价，Intellia Therapeutics盘中大涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=1170978288","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170978288?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:09","pubTimestamp":1777385355,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc今日盘中大涨5.06%，引起了市场的广泛关注。消息面上，多家券商发布了针对该公司的研究报告并上调了其目标价。其中，Canaccord Genuity将目标价从48美元上调至58美元，Leerink Partners将目标价从29美元上调至35美元。作为一家专注于基因编辑疗法的生物技术公司，Intellia Therapeutics的市场表现一直受到分析师和投资者的密切关注。此次券商集体上调目标价，进一步强化了市场对其长期发展潜力的看好。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158550621","title":"异动解读 | Intellia Therapeutics宣布增发1.5亿美元股票叠加市场预期失准，夜盘大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=1158550621","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158550621?lang=zh_cn&edition=full","pubTime":"2026-04-28 08:25","pubTimestamp":1777335940,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics今日夜盘股价大跌5.06%，引起了市场的广泛关注。消息面上，该公司宣布将启动一项承销式公开增发计划，拟出售总值1.5亿美元的普通股。此举通常会稀释现有股东的权益，是导致股价承压的直接原因之一。分析指出，鉴于该疗法是一次性高成本疗法，市场对其要求很高，股市反应反映了市场预期失准，这进一步加剧了股价的下跌压力。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145034547","title":"Intellia Therapeutics宣布拟公开增发普通股 募资1.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1145034547","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145034547?lang=zh_cn&edition=full","pubTime":"2026-04-28 04:02","pubTimestamp":1777320160,"startTime":"0","endTime":"0","summary":"生物制药领域先驱Intellia Therapeutics近日宣布，将启动一项承销式公开增发计划，拟出售总值1.5亿美元的普通股。本次增发的全部股份均由Intellia公司直接售出。本次普通股发行依据Intellia此前向美国证券交易委员会提交的S-3ASR格式自动生效注册声明进行。Intellia Therapeutics作为临床阶段的生物制药领军企业，始终致力于通过CRISPR基因编辑技术颠覆传统医疗模式。公告信息截至发布当日，公司无法律义务不主动更新内容。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4556","LU1861559042.SGD","BK4139","LU1861558580.USD","BK4588","BK4585","NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160253672","title":"异动解读 | Intellia Therapeutics基因疗法试验结果积极但市场预期失准，股价盘中大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=1160253672","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160253672?lang=zh_cn&edition=full","pubTime":"2026-04-28 03:12","pubTimestamp":1777317168,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc今日盘中股价大跌5.06%，引起了市场的关注。消息面上，该公司今日早间公布了其实验性基因编辑疗法Lonvoguran Ziclumeran针对遗传性血管水肿的3期临床试验积极结果。尽管数据积极，但分析师指出，鉴于Lonvo-Z是一次性高成本疗法，市场对其要求很高，股市反应平淡反映了市场预期失准。试验中观察到的副作用均为轻度或中度，未出现严重不良事件。Intellia预计将于2026年下半年完成该疗法的美国监管申报，若获批准，可能于2027年上半年在美国上市。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125743996","title":"Intellia Therapeutics疗法达成试验主要目标 早盘股价飙升8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1125743996","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125743996?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:37","pubTimestamp":1777289844,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc（NTLA）股价在盘前交易中大幅跃升8%，此前该公司宣布其针对罕见遗传病的实验性疗法在临床试验中达到了主要研究目标。\n这一积极数据提振了投资者对这家生物技术公司基因编辑平台潜力的信心。该疗法旨在通过精准的基因编辑技术治疗特定罕见遗传疾病，其临床试验结果标志着公司在该领域取得重要进展。\n市场对该消息反应强烈，股价的显著上涨反映出投资者对Intellia Therapeutics技术前景的乐观态度。基因编辑领域近年来备受关注，此次试验成功可能为该公司未来发展和潜在商业化奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","LU1861558580.USD","NTLA","BK4535","BK4139","BK4556","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188005880","title":"Intellia Therapeutics Inc公布Lonvo-Z三期Haelo试验达成主要及所有关键次要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1188005880","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188005880?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:12","pubTimestamp":1777288358,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc宣布，其候选疗法Lonvo-Z的三期Haelo临床试验成功达到主要研究终点以及全部关键次要终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4556","BK4585","NTLA","BK4535","LU1861558580.USD","BK4588","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195713824","title":"Intellia Therapeutics公布遗传性血管水肿3期试验积极结果，创下体内基因编辑全球首例","url":"https://stock-news.laohu8.com/highlight/detail?id=1195713824","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195713824?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:03","pubTimestamp":1777287782,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc宣布，其针对遗传性血管水肿的3期临床试验取得积极成果。这一突破性进展标志着全球范围内首次实现体内基因编辑疗法的成功应用，为基因医学领域树立了新的里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4556","LU1861558580.USD","BK4535","LU1861559042.SGD","BK4588","NTLA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160382616","title":"单次注射Lonvo-Z使多数患者六个月内摆脱疾病发作和治疗困扰","url":"https://stock-news.laohu8.com/highlight/detail?id=1160382616","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160382616?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:03","pubTimestamp":1777287781,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics公司宣布，其研发的Lonvo-Z凭借单次给药方案，成功让大多数受试患者在长达六个月的时间内无需应对疾病急性发作，同时摆脱了持续治疗的需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4556","LU1861558580.USD","BK4535","LU1861559042.SGD","BK4588","NTLA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107486234","title":"Intellia Therapeutics启动向FDA滚动提交Lonvoguran Ziclumeran（Lonvo-Z）生物制品许可申请，作为遗传性血管水肿一次性疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1107486234","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107486234?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:02","pubTimestamp":1777287740,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics公司已正式启动向美国食品药品监督管理局（FDA）滚动提交其候选疗法Lonvoguran Ziclumeran（研发代号Lonvo-Z）的生物制品许可申请。该疗法旨在作为一次性治疗手段，用于应对遗传性血管水肿。\n此次滚动提交程序的启动，标志着这款创新疗法向获批上市迈出了关键一步。若最终获得批准，Lonvo-Z有望为遗传性血管水肿患者提供一种全新的、潜在的一次性治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","BK4585","LU1861558580.USD","NTLA","BK4588","BK4556","BK4535","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167845136","title":"异动解读 | FDA解除心脏病基因疗法临床搁置，Intellia Therapeutics盘中大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1167845136","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167845136?lang=zh_cn&edition=full","pubTime":"2026-03-02 23:51","pubTimestamp":1772466703,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc  今日盘中股价大幅上涨5.01%，引起了市场的广泛关注。消息面上，美国食品药品监督管理局已解除对其治疗心脏病的实验性基因疗法后期临床试验的临床搁置。据悉，该基因编辑疗法名为nexiguran ziclumeran，旨在治疗转甲状腺素蛋白淀粉样变性心肌病。去年，因一名患者出现严重的肝脏并发症，FDA暂停了相关试验。今年1月，FDA解除了对其中一项试验的搁置，而本次解除搁置涉及第二项试验，意味着该疗法的心脏病临床试验得以全面恢复。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168319211","title":"FDA解除临床暂停后，Intellia Therapeutics盘前股价大涨7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168319211","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168319211?lang=zh_cn&edition=full","pubTime":"2026-03-02 20:45","pubTimestamp":1772455511,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）解除了对Intellia Therapeutics公司心脏病基因疗法试验的临床暂停后，该公司股价在盘前交易中上涨7%。这一监管进展为基因疗法领域注入了新的乐观情绪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1861559042.SGD","BK4585","LU1861558580.USD","NTLA","BK4556","BK4588","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188869451","title":"异动解读 | FDA解除临床试验暂停令，Intellia Therapeutics盘前大涨7.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188869451","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188869451?lang=zh_cn&edition=full","pubTime":"2026-03-02 20:34","pubTimestamp":1772454883,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc (NTLA)今日盘前股价大幅上涨7.40%，引起了市场的广泛关注。消息面上，Intellia Therapeutics宣布，美国食品药品监督管理局（FDA）已解除对其针对转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）的Magnitude三期临床试验的临床暂停令，这一决定意味着该重要临床研究项目将得以重新启动并继续推进。对于生物技术公司而言，关键临床试验的进展是影响其估值的重要因素，FDA解除暂停令被视为积极的监管进展，增强了市场对该药物研发前景的信心，从而推动了股价的显著上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTLA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.intelliatx.com","stockEarnings":[{"period":"1week","weight":-0.0232},{"period":"1month","weight":0.2483},{"period":"3month","weight":0.2176},{"period":"6month","weight":0.6224},{"period":"1year","weight":0.5144},{"period":"ytd","weight":0.8732}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":0.0084},{"period":"3month","weight":0.0963},{"period":"6month","weight":0.074},{"period":"1year","weight":0.2016},{"period":"ytd","weight":0.0931}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Intellia Therapeutics, Inc.于2014年5月在特拉华州注册成立。该公司是一家领先的基因编辑公司，专注于利用最近开发的被称为CRISPR/ Cas9的系统生物工具进行的独特的、潜在治愈疗法的发展。公司认为CRISPR/ Cas9技术具有通过单一疗程永久编辑疾病相关的基因在人体内进行改造药物的潜力。该公司打算利用其领先的科学专业知识、临床开发经验和知识产权地位解锁CRISPR/ Cas9基因编辑广泛的治疗应用，发展有潜能的新一代治疗产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.046678},{"month":2,"riseRate":0.7,"avgChangeRate":0.065016},{"month":3,"riseRate":0.2,"avgChangeRate":-0.068585},{"month":4,"riseRate":0.5,"avgChangeRate":-0.029374},{"month":5,"riseRate":0.3,"avgChangeRate":0.006419},{"month":6,"riseRate":0.909091,"avgChangeRate":0.227192},{"month":7,"riseRate":0.545455,"avgChangeRate":0.039747},{"month":8,"riseRate":0.5,"avgChangeRate":0.02106},{"month":9,"riseRate":0.2,"avgChangeRate":-0.010821},{"month":10,"riseRate":0.2,"avgChangeRate":-0.105594},{"month":11,"riseRate":0.6,"avgChangeRate":0.07833},{"month":12,"riseRate":0.3,"avgChangeRate":-0.083863}],"exchange":"NASDAQ","name":"Intellia Therapeutics Inc","nameEN":"Intellia Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Intellia Therapeutics Inc(NTLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Intellia Therapeutics Inc,NTLA,Intellia Therapeutics Inc股票,Intellia Therapeutics Inc股票老虎,Intellia Therapeutics Inc股票老虎国际,Intellia Therapeutics Inc行情,Intellia Therapeutics Inc股票行情,Intellia Therapeutics Inc股价,Intellia Therapeutics Inc股市,Intellia Therapeutics Inc股票价格,Intellia Therapeutics Inc股票交易,Intellia Therapeutics Inc股票购买,Intellia Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Intellia Therapeutics Inc(NTLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}